STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

STAT PlusNewsletterPharmalot Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more Hims & Hers plans to enter the peptides market before the end of the year Manage alerts for this article Email this article Share this article By Ed SilvermanAug. 11, 2026 Pharmalot Columnist, Senior Writer Ed Silverman[email protected]Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again. And to celebrate, we are brewing still more cups of stimulation and inviting you to join us.

Our choice today is blackberry hibiscus. Remember, a prescription is not required. So no need to mess with rebates or even TrumpRx.

Meanwhile, here are a few items of interest. Hope you have a meaningful and productive day and, of course, do stay in touch. … The U.S.

Food and Drug Administration rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis, STAT notes. The drug had been developed by ITM Isotope Technologies Munich SE, a long-standing player in the field of radiopharmaceuticals, which are an emerging treatment designed to shoot radioactive isotopes directly at tumor cells. The company had been anticipating the FDA would sign off on the drug and last month launched a new division, Lumara Bio, to commercialize and sell it.Advertisement Hims & Hers plans to jump into the peptides market before the end of the year, seeing opportunity to seize on a booming corner of the health industry, Bloomberg News says.

The telehealth company is preparing to sell already-allowed popular compounds that patients seek for wellness and longevity benefits despite limited clinical evidence. The plan comes as the FDA decides whether to loosen restrictions on seven different compounds. Last month, the agency held a hearing in which outside advisers recommended easing limits on production and expanding access.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In pharmalittle, STAT+ Submit a correction requestReprints Ed Silverman Pharmalot Columnist, Senior Writer Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Pharmalot August 10, 2026 STAT Plus: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more Exclusive August 9, 2026 STAT Plus: A shortage of two Sanofi medicines for Pompe disease rattles patients Advertisement Pharmalot August 7, 2026 STAT Plus: Up and down the ladder: The latest comings and goings August 7, 2026 STAT Plus: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more Pharmalot August 6, 2026 STAT Plus: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts Subscriber Picks